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Abstract: Carotenoids are among the most abundant natural pigments available in nature. These
pigments have received considerable attention because of their biotechnological applications and,
more importantly, due to their potential beneficial uses in human healthcare, food processing,
pharmaceuticals and cosmetics. These bioactive compounds are in high demand throughout the
world; Europe and the USA are the markets where the demand for carotenoids is the highest. The
in vitro synthesis of carotenoids has sustained their large-scale production so far. However, the
emerging modern standards for a healthy lifestyle and environment-friendly practices have given
rise to a search for natural biocompounds as alternatives to synthetic ones. Therefore, nowadays,
biomass (vegetables, fruits, yeast and microorganisms) is being used to obtain naturally-available
carotenoids with high antioxidant capacity and strong color, on a large scale. This is an alternative to
the in vitro synthesis of carotenoids, which is expensive and generates a large number of residues,
and the compounds synthesized are sometimes not active biologically. In this context, marine
biomass has recently emerged as a natural source for both common and uncommon valuable
carotenoids. Besides, the cultivation of marine microorganisms, as well as the downstream processes,
which are used to isolate the carotenoids from these microorganisms, offer several advantages over
the other approaches that have been explored previously. This review summarizes the general
properties of the most-abundant carotenoids produced by marine microorganisms, focusing on
the genuine/rare carotenoids that exhibit interesting features useful for potential applications in
biotechnology, pharmaceuticals, cosmetics and medicine.
Keywords: carotenoids; antioxidants; bioactive compounds; blue biotechnology; marine microorganisms
1. Introduction
Carotenoids are a class of pigments distributed ubiquitously in nature [1]. These pigments have
received considerable attention because of their biotechnological applications and, more importantly,
due to their potential beneficial applications in the fields of human healthcare, food processing,
pharmaceuticals and cosmetics [2,3]. Chemically, these compounds are mainly C40 lipophilic
isoprenoids that range from colorless to yellow, orange and red [1,2,4]. These pigments may be
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categorized into two groups based on the presence or absence of oxygen in their structures: carotenes
(do not contain oxygen) and xanthophylls (contain oxygen). The production of these pigments from
plants, fungi and certain microorganisms, on a medium-scale level, and even on a large-scale level,
has been described previously [5–11]. In fact, the studies focused on the regulation of carotenogenesis,
the biological roles performed by the carotenoids, the general characterization of the carotenoids and
the analytical procedures utilized in order to describe their structure are abundantly available in the
literature [1,12,13].
Carotenoids have received much attention because of the variety of important biological roles
they perform in all living systems [1,14–16]. In the majority of organisms, the most relevant biological
functions performed by the carotenoids are associated with their antioxidant properties, which are
a direct outcome of their molecular structure [10]. Xanthophylls, for instance, perform the role
of free-radical scavengers, potent quenchers of ROS (reactive oxygen species) and RNS (reactive
nitrogen species) and chain-breaking antioxidants. Therefore, astaxanthin and canthaxanthin (which
are xanthophylls) are better antioxidants and scavengers of free radicals compared to β-carotene. In
recent years, understanding the ROS-induced oxidative stress mechanisms and the search for suitable
strategies in order to fight oxidative stress have become the major goals of medical research efforts [10].
Furthermore, carotenoids are the natural compounds that are responsible for conferring color to
animals, plants and microorganisms [17].
Animals, as well as humans are not capable of synthesizing the carotenoids de novo; the
pigments are, therefore, acquired through diet. However, they are capable of converting these
pigments into vitamin A and the retinoid compounds, which are required for morphogenesis
and embryonic development [18,19]. Vitamin A is a well-recognized factor of great importance
in child health and survival; its deficiency causes disturbances in vision and also lung, trachea
and oral cavity pathologies. Consuming carotenoids through diet is the only way to carry out
retinol synthesis in animals and humans; fruits, vegetables and microalgae being the major sources
of carotenoids that exhibit pro-vitamin A activity [10,19]. Other biological roles and functions
performed by the carotenoids in animals and humans include absorption of light energy, oxygen
transport [20], enhancing in vitro antibody production and antitumor activity [21,22] and antioxidant
and anti-inflammatory activities [23].
In birds and fishes, carotenoids are an important indication of a satisfactory nutritional condition
and are used in ornamental displays as a sign of fitness and to increase sexual attractiveness [16,24,25].
In algae and higher plants, carotenoids serve as the regulators of plant growth and development,
the accessory pigments for photosynthesis and as photoprotectors. Thus, they contribute to
light harvesting, maintenance of the structures and functions of the photosynthetic complexes,
quenching of the chlorophyll triplet states, scavenging of reactive oxygen species and dissipation
of excess energy [26]. Besides, carotenoids also serve as precursors for certain hormones such as
abscisic acid (ABA) and strigolactones, as well as attractants for other organisms, such as insect
pollinators and seed-dispersing herbivores [19]. Apart from the above-mentioned important roles,
carotenoids also serve as important floral pigments, due to their striking and rich color, to attract
pollinators and seed dispersers. Microorganisms are a great source of a variety of carotenoids. In
microorganisms, carotenoids oversee photoprotection, provide color to microbial cells and regulate
the mechanisms against oxidative stress. It is important to highlight that certain carotenoids, such as
salinixanthin or bacterioruberin (produced by halophiles), are produced solely by certain extremophilic
microorganisms [8,27,28].
For the last 30 years, researchers and the R&D companies have paid much attention to the
microorganisms that are capable of producing significant concentrations of carotenoids, because these
biocompounds obtained from these natural sources are in high demand these days. This huge demand
is a result of consumers’ preference for natural as opposed to synthetic products. Such demand has
encouraged the production of scientific literature on novel carotenoid-producing microorganisms and
has prompted major efforts to enhance the isolation of carotenoids from their biological sources instead
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of their chemical synthesis. This fact, coupled with fresh insights into the molecular biology techniques
and downstream processes, epitomizes the carotenoid-producing microorganisms as suitable natural
sources for the large-scale synthesis of carotenoids, as an alternative to in vitro carotenoid production.
Among all the natural sources of carotenoids, marine microorganisms have emerged as the natural
sources from which the production of these pigments may be relatively easy.
This review is an attempt to compile the latest studies and research works in this field.
It summarizes the main findings that have been described to date about the marine microbial
carotenoids, highlighting their potential beneficial effects on human health and their relevance in the
natural compounds market.
2. Marine Microorganisms as a Source of Bioactive Compounds
Bioactive compounds are the compounds that produce specific effects within a living organism,
tissue or cell. In the field of nutrition, bioactive compounds have been distinguished from essential
nutrients; essential nutrients are necessary for the sustainability of life, while bioactive compounds
are not. However, bioactive compounds may have an influence (usually positive) on metabolism
and on health in general. Bioactive compounds are usually the secondary metabolites produced by
microorganisms, yeast, algae and fungi [29].
Marine life forms have long adapted their physiology and metabolism to the extreme ambient
conditions present in the seas, oceans and other closely-related environments, such as marshes, coastal
salt ponds, etc. Consequently, they have evolved within themselves protective mechanisms that include
the accumulation of bioactive compounds [30,31]. Recent research on marine ecosystems has revealed
that the marine aquatic biomass (free-living cells or symbiotic) and its bioactive compounds have
many potential applications in various fields; for example, ensuring future food and nutrition security
and supplying raw materials for other high added-value chains and products, such as bioenergy,
pharmaceuticals and cosmetics, while factoring in the environmental and climate change risks.
Therefore, international institutions, such as the European Commission, are promoting
investigations in the field of biotechnology in general, particularly in blue biotechnology, a field
that is concerned with the exploration and exploitation of the resulting diversity of marine organisms
in order to develop novel products [32]. Besides, a significant number of research groups are working
in a coordinated manner to improve the knowledge about carotenoids and the novel natural sources
for their production, as is evident from the presence of networks such as Eurocaroten [33], CaRed (the
Spanish Carotenoid Network; [34], the International Carotenoid Society [35] and IBERCAROT (the
Ibero-American network for the study of carotenoids as functional food ingredients, [36]).
In line with this fact, the microorganisms that produce a significant amount of bioactive
compounds (lipids, carotenoids, vitamins, etc.) are abundant in the marine environment; therefore,
they are considered suitable targets for exploring their potential as the natural biosources from
which carotenoids may be obtained at a large scale [37–39]. Besides, modern approaches such as
genomics, transcriptomics, proteomics, etc., have been recently used as powerful tools to investigate
the production of bioactive compounds from marine organisms [40–42]. Therefore, marine plants
(kelp, for instance), phytoplanktons, marine algae and microorganisms such as marine bacteria and
Haloarchaea, are perceived as attractive sources for the production and isolation of common, as well
as novel and rare carotenoids (Table 1).
Marine microorganisms, in addition to their capacity to synthesize unique bioactive compounds,
offer certain advantages specific to a large-scale production of carotenoids; for example, the risk of
contamination with other microorganisms is reduced due to the high-salinity conditions used in
their culture media [43]. This feature becomes more significant when the extreme halophilic marine
microorganisms such as Haloarchaea are used as the natural source of bioactive compounds [8,44].
However, the concern is to produce the bioactive compounds at a price that is competitive; which is
difficult because the production costs of the microbial biomass are high. Therefore, further investigation
is required to achieve a more profitable production of the bioactive compounds.
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Table 1. Microorganisms that produce carotenoids in the marine environment and biological properties
with potential benefits for human health.
Abundant Carotenoids in the Marine Environment
Marine Microorganism Carotenoid Biological Properties References
• Microalgae
• Bacteria
• Cyanobacteria
β-Carotene
Antioxidant immune response
Anti-inflammatory
Benefits for cognitive function and atherogenesis
Antidiabetic activity
Antitumor activity
[10,45–47]
• Haloarchaea
• Bacteria
• Cyanobacteria
• Microalgae
Astaxanthin
Immune response anti-inflammatory
Antioxidant activity
Antitumor activity
Ocular protective effect
Antidiabetic activity
Against:
# benign prostatic hyperplasia
# cancer
# asthma
# rheumatoid arthritis
# metabolic syndrome
# diabetic nephropathy
# cardiovascular diseases
# neurodegenerative diseases
[8,48–55]
• Microalgae Fucoxanthin
Reduction of cardiovascular risk factors
Electron donor
Involved in lipid metabolism increasing production
of energy
Antioxidant activity
Anti-inflammatory effect
Anticancer activity
Anti-obese effect
Antidiabetic activity
Hepatoprotective effect
Skin-Protective effect
Antiangiogenic effect
Cerebrovascular protective effect
Bone-protective effect
Ocular protective effect
Antimalarial effect
[15,51,56–60]
• Microalgae
• Bacteria
• Cyanobacteria
Zeaxanthin
Reduction of cardiovascular risk factors
Prevention of coronary syndromes
Helps in maintaining visual function
Antitumor activity (breast cancer)
Anti-cardiovascular diseases
Antioxidative, anti-inflammatory and structural actions
in neural tissue
[15,61–65]
• Cyanobacteria β-Cryptoxanthin
Antioxidant
Immune response anti-inflammatory
Improves respiratory function and lowers lung
cancer rates
Stimulation of bone formation
Reduces the rate of oral and pharyngeal cancer
Modulation response to phytosterols in
post-menopausal women
Protection of leukocyte telomeres’ length
Decreases risk of some cancers and degenerative diseases.
Bone-protective effect
[15,66–71]
Less abundant carotenoids in the marine environment
• Haloarchaea Bacterioruberin AntioxidantAnticancer activity [8]
• Bacteria Saproxanthin AntioxidantApoptosis-inducing effect [15,72]
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Table 1. Cont.
Abundant Carotenoids in the Marine Environment
Marine Microorganism Carotenoid Biological Properties References
• Cyanobacteria
• Bacteria Myxol
Antioxidant
Anticancer activity
Against cardiovascular pathologies
[15,73]
• Actinomycetes Sioxanthin Antioxidant [74]
• Microalgae
• Haloarchaea Lutein
Antioxidant
Anti-macular eyes degradation
Prevention coronary syndromes and stroke
Prevention of cataract
Prevention of retinitis
Ocular protective effect
Dopaminergic neurons protection against MPTP-induced
apoptotic death
Anti-atherosclerosis
[8,15,62,74–77]
• Microalgae
• Cyanobacteria
• Haloarchaea
• Bacteria
Canthaxanthin
Antioxidant
Antitumoral activity
Provitamin A activity
[8,46,51,78–80]
• Microalgae
• Cyanobacteria Echinenone Antioxidant [51,74,81]
• Microalgae Violaxanthin Food additive E161e (not approved in the EU and USA)Anti-inflammatory effects in macrophages [74,82]
• Microalgae
• Haloarchaea
• Bacteria
Phytoene Antitumoral activity [8,78,83]
• Microalgae
• Bacteria Lycopene
Reduction risk of atherosclerosis and coronary
heart disease
Antioxidant activity
Antiulcer activity
Gene regulation
Gap-junction communication activity
Immune modulation
Antitumor activity
[8,84–86]
• Microalgae
• Haloarchaea Salinixanthin
Anticancer activity (human liver cancer cell lines showed
dose-dependent cytotoxicity of the carotenoids) [8]
3. Properties of the Most Demanded Carotenoids Isolated from Marine Microorganisms
This section summarizes the general aspects of the carotenoids that are most demanded in the
pharmaceutical, cosmetics and biotechnological markets. These are known as the common carotenoids.
These carotenoids are present in marine microorganisms, as well as in other organisms, such as
terrestrial plants, aquatic plants, fungi, yeast, etc. Although these carotenoids have been obtained
mainly from plants, fungi, yeast and algae, several recent works on microorganisms (mainly from the
marine environments) have revealed that certain microbial genera are the producers of significantly
large amounts of several carotenoids with potential applications in biomedicine and biotechnology.
Table 2 enlists the main features of the structure of each of the following carotenoids.
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Table 2. IUPAC name, molecular formula and chemical structure of the most marketed carotenoids.
Common Name IUPAC Name Molecular Formula Chemical Structure Reference
Astaxanthin 3,3
′-Dihydroxy-β,β-carotene-
4,4′-dione C40H52O4
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Table 2. Cont.
Common Name IUPAC Name Molecular Formula Chemical Structure Reference
Fucoxanthin
3,5′-Dihydroxy-8-oxo-6′ ,7′-
didehydro-5,6-epoxy-5,6,7,8,5′ ,6′-
hexahydro-β,β-caroten-3′-yl acetate
C42H58O6
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3.1. Astaxanthin
Astaxanthin (3,3′-dihydroxy-β,β’-carotene-4,4′-dione) is a red-pink-colored xanthophyll
carotenoid, which contains two additional oxygenated groups on each ring compared to the other
carotenoids, which results in enhanced antioxidant properties of this compound [56]. It is a β-carotene
derivative, which is eleven-times more potent as a quencher of singlet oxygen than β-carotene and
550-times more potent than α-tocopherol [54]. Astaxanthin exhibits a higher biological activity than
the other antioxidants, because of its ability to link across the entire cell membrane from the inside
to the outside [87]. This compound occurs naturally in a wide variety of living organisms, including
microalgae, fungi, plants, marine organisms and certain birds such as flamingos; it confers salmon,
shrimp and lobster their distinctive color [54]. Astaxanthin can neither be synthesized de novo by
animals, nor converted into vitamin A; therefore, it must be consumed in the diet [56]. The high
potency, as well as the polar property of astaxanthin makes it an attractive antioxidant nutraceutical
suitable for further investigation in the field of biomedicine. Several works have demonstrated that
astaxanthin, when used as a nutritional supplement (it is associated with the E number E161j), has
potential beneficial effects on human health. The biotechnological production of astaxanthin from
various sources has been studied in depth [88] in order to achieve its production on a large scale for
several commercial applications [87]. The astaxanthin products are used for commercial applications in
dosage forms, such as tablets, capsules, syrups, oils, soft gels, creams, biomass and granulated powders.
Astaxanthin-related patent applications are available in the areas of food, feed and nutraceuticals and
are currently the major market driver for the pigment.
3.2. β-Carotene
β-Carotene is an intensely-colored orange pigment, abundant in green leafy plants (parsley,
spinach, broccoli), certain fruits (mandarin, peach) and several vegetables (carrot, pumpkin) [26].
Its distinguishing characteristic is the beta rings present at both ends of the molecule. β-Carotene
occurs as several isomers, two of which (9-cis and all-trans) constitute approximately 80% of the total
β-carotene present in the microalga Dunaliella bardawil [89]. β-Carotene is used as a food coloring
agent with the E number E160 [90]. In nature, β-carotene is a precursor (inactive form) of vitamin A,
which is synthesized from carotenoids via the action of the enzyme β-carotene 15,15′-monooxygenase.
Following its synthesis, vitamin A is assimilated or further converted into retinoids so that it does not
cause hypervitaminosis A. The isolation of β-carotene from fruits is commonly performed by using
column chromatography [91,92]. β-Carotene is deeply colored and a highly-conjugated carotenoid,
which lacks functional groups, causing it to be highly lipophilic. Overconsumption of β-carotene may
cause carotenosis, a benign condition under which the skin turns orange. Chronic intake of high doses
of β-carotene supplementation has been correlated directly with the increase in the probability of lung
cancer in cigarette smokers [93].
3.3. Canthaxanthin
Canthaxanthin (β,β-carotene-4,4′-dione) is a diketo carotenoid pigment, which is orange-red
in color. It was first isolated from edible mushrooms. In several green algae and also in blue-green
algae, this pigment is produced as a secondary carotenoid at the end of the growth phase, either in
place of, or in addition to, the primary carotenoids. It has also been found in bacteria, crustaceans,
birds (even in the yolk of bird eggs) [94] and in various species of fish, including the common carp
(Cyprinus carpio), golden mullet (Mugil auratus), annular seabream (Diplodus annularis) and thrush
wrasse (Crenilabrus tinca) [57]. It is used as a food coloring agent, associated with the E number E161g,
in different countries, including the United States and the EU member states. As canthaxanthin has a
high commercial value, its biosynthesis has been studied extensively. Canthaxanthin is biosynthesized
from β-carotene, through the action of a single enzyme, known as β-carotene ketolase, which adds
carbonyl groups to the carbon atoms at the 4 and 4′ positions in the β-carotene molecule. Although
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functionally identical, several distinct β-carotene ketolase proteins are known, which differ (from an
evolutionary perspective) in their primary protein/amino acid sequence. In order to improve the
large-scale canthaxanthin production using microorganisms, the regulation of its biosynthesis has been
studied recently in Haematococcus pluvialis [95] and in Dietzia natronolimnaea [96,97].
3.4. β-Cryptoxanthin
β-Cryptoxanthin (hydroxy-β-carotene) occurs in a variety of sources, including petals of flowers
and several fruits such as papayas, satsuma mandarins and apples [57]. It is present together with
α-carotene, β-carotene, lycopene, lutein and zeaxanthin. It is also present in egg yolk [98] and
sweet oranges [99]. β-Cryptoxanthin is a good source of vitamin A, and therefore, it is considered
a pro-vitamin A [100]. This carotenoid is oxidized and isomerized in the presence of light [101].
β-Cryptoxanthin is used as a coloring agent to color food products in certain countries and is
associated with the E number E161c. β-Cryptoxanthin obtained from its common food sources,
exhibits relatively high bioavailability to the extent that certain β-cryptoxanthin-rich foods might be
considered equivalent to β-carotene-rich foods as sources of retinol [102].
3.5. Fucoxanthin
Fucoxanthin is one of the most abundant carotenoids, and it is present as an accessory pigment in
the chloroplasts of brown algae, phytoplankton, brown seaweeds and diatoms, giving them a brown
or olive-green color [58]. It shares more than 10% of the estimated total production of carotenoids
in nature, especially in the marine environments [57]. Fucoxanthin is a xanthophyll with a unique
structure that includes an unusual allenic bond, an epoxide group and a conjugated carbonyl group in
the polyene chain, conferring it the antioxidant properties. However, the difference is that fucoxanthin
exhibits antioxidant properties even under anoxic conditions, while the other carotenoids demonstrate
practically no quenching ability under those conditions. Most of the tissues have a low-oxygen status
under physiological conditions. Consequently, fucoxanthin may be performing key roles under anoxic
conditions. The unique molecular structure of fucoxanthin confers remarkable biological properties
to it, similar to neoxanthin, dinoxanthin and peridinin. Fucoxanthin does not exhibit toxicity and
mutagenicity under experimental conditions, and it may possess the ability to increase the levels
of circulating cholesterol in rodents as a common feature [57]. Fucoxanthinol is the deacetylated
derivative of fucoxanthin. In fact, it has been reported that several of the bioactive properties of
fucoxanthin are due to fucoxanthinol [58,103–106]. Fucoxanthinol exhibits suppressive effects on
lipid accumulation during adipocyte differentiation, and it also demonstrates anti-inflammatory and
antioxidative properties.
3.6. Lycopene
Lycopene (ψ,ψ-carotene) is responsible for the red color in several fruits and vegetables, such
as tomatoes. Unlike certain other carotenoids, lycopene lacks the terminal β-ionone ring in its
structure, and therefore, provitamin A activity is not present in this carotenoid. Lycopene has a
highly unsaturated, hydrocarbon chain, consisting of eleven conjugated and two unconjugated double
bonds, which confers its antioxidant activity. Because of the presence of the double bonds in the
structure of lycopene, it can exist in both cis and trans isomeric forms. In nature, lycopene is present
primarily in the all-trans isomeric form. However, it may undergo mono- or poly-isomerization in the
presence of light, thermal energy and temperature, which can convert it to the cis isomer. Lycopene
is highly stable under the conditions of thermal processing and storage. It has been reported that
5-cis lycopene is the most stable isomer of lycopene, followed by the all-trans, 9-cis, 13-cis, 15-cis, 7-cis
and 11-cis isomeric forms. The 5-cis isomer of lycopene has been demonstrated to exhibit the highest
antioxidant activity, followed by the 9-cis, 7-cis, 13-cis, 11-cis and all-trans isomers [85]. Lycopene is
associated with the E number E160d when used as a coloring agent for food products.
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3.7. Lutein
Lutein (β,ε-carotene-3,3′-diol) is one of the two major components of the macular pigment of
the retina and is present at a high concentration in the human serum [107]. It is synthesized only by
plants, and similar to the other xanthophylls, it is present in high quantities in green leafy vegetables,
such as spinach and kale, and yellow carrot. In green plants, lutein modulates light energy and
serves as a non-photochemical quenching agent to deal with triplet chlorophyll (an excited form of
chlorophyll), which is overproduced at high light intensity during photosynthesis. Lutein contains
only 10 conjugated double bonds, which causes it more yellowish-green color compared to the other
carotenoids. Lutein acts as a powerful antioxidant and is able to filter high-energy blue light [108].
When used as a food colorant, it is associated with the E number E161b. Recently, novel methodologies
have been developed and optimized in order to isolate this pigment from vegetables, for example from
spinach [109] or carrot [92].
3.8. Zeaxanthin
Zeaxanthin (β,β-carotene-3,3′-diol) is one of the most common carotenoid alcohols present in
nature, which performs an important role in the xanthophyll cycle. It is synthesized by plants and
certain microorganisms. Zeaxanthin is the pigment that confers paprika (produced from bell peppers),
corn, saffron, wolfberries and several other plants and microorganisms (such as marine bacteria) their
characteristic color [110]. It is also one of the two major components of the macular pigment of the
retina. Zeaxanthin is isomeric with lutein, and the two carotenoids differ from each other only in the
location of a single double bond; in zeaxanthin, all the double bonds are conjugated. Zeaxanthin does
not exhibit vitamin A activity. This pigment and its close relative lutein perform a critical role in the
prevention of AMD (age-related macular degeneration), one of the leading causes of blindness [57].
Like lutein, zeaxanthin has been found in significant concentrations in human milk [111]. Because of its
high value and demand in the nutraceutical market, several methods have been developed to produce
zeaxanthin on a large scale [112]. As a food colorant, it is associated with the E number E161 h.
3.9. Violaxanthin
Violaxanthin (5,6:5′,6′-diepoxy-5,5′,6,6′-tetrahydro-β-carotene-3,3′-diol) is a natural xanthophyll
pigment, which is orange in color. It is present in a variety of brown algae and in plants including
pansies. This pigment is biosynthesized from zeaxanthin through the process of epoxidation.
As a food additive, it is used under the E number E161e; however, this use is approved only in
Australia and New Zealand, where it is listed under the INS number 161e. The interconversions of
violaxanthin and zeaxanthin are caused mainly by the action of the violaxanthin de-epoxidase enzyme.
Violaxanthin de-epoxidation and the violaxanthin cycle were first studied in the late 1960s to the early
1970s [113–115]. Violaxanthin de-epoxidases are susceptible to DTT [116,117], and their thermostability
is due to the disulfide bridges present in their structures [118]. These interconversion mechanisms
have been observed to correlate directly to the dissipation of excess excitation energy in leaves in 2%
O2, 0% CO2 [119]. So far, the major biological roles of violaxanthin, as well as its role as a precursor of
abscisic acid, have been described using leaves [120] and fruits [121] as the sources of this carotenoid.
4. The Rare Carotenoids
The rare carotenoids include certain carotenoids recently found in only a few marine organisms,
at the time of writing this review. Although there are probably several rare carotenoids to be described,
only a few of them have been reported so far in the previous studies. The production of the biomass
of marine organisms that contain the rare carotenoids is the first step toward the biotechnological
production of these carotenoids. All the rare carotenoids that have been described so far were isolated
mainly from microalgae or Haloarchaea (the halophilic microorganisms belonging to domain Archaea,
which inhabit salty environments). So far, there are no examples of a large-scale production of rare
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carotenoids from microalgae, and only one indexed paper has reported the cultivation of Nostoc for
this purpose [122]. Several wild-types, as well as genetically-engineered species of Nostoc, have been
used to investigate the production of exopolysaccharides, such as polyhydroxyalkanoates [123], and
the production of hydrogen [124]. Moreover, several species of Anabaena have also been reported to
serve as attractive sources for the production of exopolysaccharides [125] and carotenoids as feedstock
for biodiesel [126]. However, the production of rare carotenoids from Nostoc and Anabaena, as well as
the processes for the large-scale production of their biomass have not yet developed completely.
Other rare carotenoids, such as bacterioruberin (and its derivatives) or salinixanthin, are produced
mostly from Haloarchaea [8]. The recent works reported by Shindo and by Gamone and co-workers
have referred to myxol, saproxanthin, sioxanthin and siphonaxanthin as rare carotenoids [15,127].
The main features describing each of the above-mentioned rare carotenoids are summarized in the
following sections, as well as in Table 3.
4.1. Bacterioruberin
Bacterioruberin is the main carotenoid responsible for the color of the red halophilic Archaea
belonging to the families Halobacteriaceae and Haloferacaceae. To date, the production of this rare
carotenoid has been reported only from the Haloarchaea and Micrococcus roseus [8,128]. Bacterioruberin
is a C50 carotenoid pigment, exhibiting a unique molecular structure. It consists of a primary conjugated
isoprenoid chain with 13 C=C units and no subsidiary conjugation arising from the terminal groups,
which contain only four hydroxyl groups [8]. This pigment protects the microbial cells against the
damage caused by high intensities of light in the visible and the ultraviolet range of the spectrum, and it
also aids in photoreactivation [129]. The pigment is also involved in the reinforcement of the microbial
cell membrane. This pigment was first described from the cells of a Halobacterium species [130]. Recent
works on the production of bacterioruberin from Haloarchaea report that the production of this rare
carotenoid may be easily enhanced by modifications of the temperature, salt concentrations, pH,
oxygen availability or light incidence [8,44].
4.2. Myxol
Myxol is derived from γ-carotene. It is present in various forms in nature; however, as free
myxol, it is present mainly in the marine environments. The marine bacterium MBIC 03313 was
reported as the first microorganism to produce free myxol. Anabaena variabilis ATCC 29413 also
produces this pigment, along with 4-hydroxymyxol [131]. Robiginitalea myxolifaciens sp. nov. has been
reported to be capable of producing myxol in sea water [132]. Myxol, in its glyoxylated form, has been
identified in both marine and non-marine aquatic microorganisms such as Nostoc commune [133]. The
freshwater alga Oscillatoria limosa produces myxol-glyoxylate as myxol-2′-O-methyl-methylpentoside
and 4-keto-myxol-2′-methylpentoside [73]. The potential applications of myxol in the area of human
health are related to its strong antioxidant activity. Myxol and saproxanthin have demonstrated better
antioxidant activity against lipid peroxidation and better neuroprotective effects against L-glutamate
toxicity than β-carotene or zeaxanthin, in a rat brain homogenate model [134]. The antioxidant activity
of myxol has also been associated with its capacity to decrease the oxygen permeability in lipid
membranes [15].
4.3. Salinixanthin
This carotenoid is produced mainly by the halophilic bacterium Salinibacter ruber and by certain
halophilic Archaea species belonging to the Halobacteriaceae and Haloferacaceae families [8,28,135].
The structure of salinixanthin ((all-E,2′S)-2′-hydroxy-1′-[6-O-(13-methyltetradecanoyl)-β-D-
glycopyranosyloxy]-3′,4′-didehydro-1′,2′-dihydro-β,Ψ-caroten-4-one) was first determined using
spectroscopic techniques [136]. In nature, this carotenoid functions as a light-harvesting antenna for
supplying the additional excitation energy for retinal isomerization and proton transport [137].
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4.4. Saproxanthin
Saproxanthin is a xanthophyll carotenoid. It was first reported and described by Aasen and
Jensen in Saprospira grandis. A selected strain of Saprospira sp., SS90–1, which was identified as
Saprospira toviformis, synthesizes saproxanthin as a major pigment [138]. The marine bacterial strain
04OKA–13–27 was reported as the second species to produce saproxanthin [127,134]. More recently, it
was reported that alkaline conditions improved the synthesis of this rare carotenoid in the bacterial
strains belonging to Jejuia pallidilutea [139].
4.5. Sioxanthin
Sioxanthin has been reported to be produced so far only by a marine actinomycete belonging to
the genus Salinispora. It was described that this pigment has a novel C40 carotenoid structure, which
is glycosylated at one end of the molecule, and contains an aryl moiety at the other end. Glycosylation
is unusual among the actinomycete carotenoids, and therefore, sioxanthin forms a part of the rare
group of compounds that possess polar, as well as non-polar head groups [140].
4.6. Siphonaxanthin
Siphonaxanthin is a keto-carotenoid, a xanthophyll pigment that is present in the species belonging
to the Siphonales order [15,141]. Siphonales are the green algae present in both marine and freshwater
environments and are quite common in deep, as well as shallow waters [142,143]. To date, the
species that belong to this order are the only ones identified as the producers of siphonaxanthin. The
characterization of this rare carotenoid remains poorly explored; nevertheless, several recent works
have stated that siphonaxanthin could be considered a bioactive compound with potential beneficial
effects on human health [15,144].
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Table 3. IUPAC name, molecular formula and chemical structure of the rare carotenoids.
Common Name IUPAC Name Molecular Formula Chemical Structure Reference
Bacterioruberin
(2S,2′S)-2,2′-Bis(3-hydroxy-3-methylbutyl)-
3,4,3′ ,4′-tetradehydro-1,2,1′ ,2′-tetrahydro-
y,y-carotene-1,1′-diol
C50H76O4
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5. Carotenoids and Human Health
To date, more than 6000 works on the effects of carotenoids on human health have been published
in the indexed scientific journals (PubMed: 6500; Scopus 3000; and WOS: 5978; “carotenoids” and
“human health” were used as keywords to perform the search). Most of the studies have reported the
general characterizations of carotenoids using biochemical techniques and the conclusions regarding
their potential benefits [17]. In certain other works, the potential effects of carotenoids on cell lines
or animal models have been described. Basically, only one-third of the research currently published
in this area of study has been conducted in humans. Therefore, so far, the studies demonstrating
a direct correlation between the carotenoid uptake and the beneficial effects on human health are
scarce. Another important aspect that needs to be highlighted here is that the assays that are used to
analyze the carotenoids in the human body must be optimized, as several of the studies continue to
use empirical prediction models instead of real-time measurements in human fluids or tissues [145].
Consequently, further research is required in both basic and applied aspects.
The few connections that have been established directly between carotenoid consumption and
the human health reveal that: (i) these pigments are powerful antioxidants, and consequently, they
could possess antitumor activity; (ii) certain carotenoids exhibit pro-vitamin A activity; and (iii) certain
carotenoids may be able to demonstrate regulatory activities at different levels in several tissues,
and because of this regulatory role, they may exhibit a protective effect against the development of
degenerative diseases, such as macular degeneration, cancer and heart diseases [15], or they may
be able to prevent metabolic diseases, such as type 2 diabetes or dyslipidemia [146,147]. Table 1
summarizes the major potential beneficial effects of carotenoids (or their derivatives) on human health,
as described by various studies, to date.
Nowadays, consumers are aware of the association among diet, health and the prevention of
diseases [147]. As a result, bioactive compounds, such as antioxidants, peptides, carbohydrates and
lipids, present in food have become important for human nutrition and the reason for the development
of functional foods and nutraceuticals in the food industry. The terms such as “health-promoting foods”
or “functional foods” refer to food that is rich in bioactive compounds and substances that are effective
against diseases [148]. The outer appearance of these functional foods is similar to conventional foods;
however, the difference is that functional foods offer advantages beyond the basic nutritional functions;
they exhibit physiological benefits and are able to reduce the risk of chronic diseases [149]. The term
“nutraceutical” was coined by combining two terms, “nutrition” and “pharmaceutical”, in 1989 [150];
nutraceuticals are defined as “a food (or a part of food) that provides medical or health benefits,
including the prevention and/or treatment of a disease” [150]. When the functional food aids in the
prevention and/or treatment of a disease(s) and/or a disorder(s) other than anemia, it is referred to as
a “nutraceutical” [151]. It is important to note that functional foods may not be a universal panacea
for poor health habits [152]. In brief, health benefits and novel markets in the food industry may be
obtained by incorporating carotenoids into foods that do not contain high amounts of these natural
pigments; also, when added to food, the bioavailability of carotenoids is improved compared to when
they are consumed from their natural sources [153].
The interest in marine-derived functional foods has increased, especially the functional foods
from marine algae, which are considered an interesting source of bioactive compounds with biological
properties to be used as functional food ingredients. Taking into consideration all of these aspects,
carotenoid-rich foods, such as the Mediterranean diet, are being regarded as the best diet models for
supporting healthy living standards and to promote the positive effects on human health, for instance
cardiovascular health [15]. Host-related factors may also affect the capability to absorb, convert and
metabolize dietary carotenoids. Factors such as gender, body fat and genetic variation may also play
important roles in these processes.
It is noteworthy that several recent works have stated that the intake of food supplements
without professional supervision is associated with certain problems, such as side effects caused when
the supplements interact with classical synthetic drugs [154]. The excessive intake of carotenoids
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causes carotenemia in humans, which is benign. Moreover, unusual diets and the consumption of
preformed vitamin A present in the food supplements may lead to vitamin A toxicity [155,156]. In
summary, a significant number of previous studies support the use of food supplements, nutraceuticals
and carotenoid-rich foods; however, in all cases, the consumption of these supplements must be
accompanied by professional/medical supervision.
6. Marine Microalgae Biomass and Their Valuable Molecules in the Food Market
Microalgae have been used as food, feed and fertilizers for centuries. Their cultivation on a large
scale may be extended to areas that are unsuitable for agricultural purposes, with productivities
higher than those obtained with traditional crops [9]. Marine microalgae are rich in PUFAs
(poly-unsaturated fatty acids), polysaccharides, sterols and pigments such as carotenoids, chlorophylls
and phycobiliproteins [157,158] that could be used to increase the nutritional value of foods [159].
Antioxidants have become a major focus of interest, and several studies have associated antioxidant
activity with carotenoid content in algae [160], which has resulted in an increased demand for algae in
order to obtain carotenoids to be added to functional foods.
The global market for carotenoids is expected to reach U.S. $1.7 billion by the year 2022. The
market size of functional foods derived from microalgae has increased five-fold since the beginning
of the century, and its development has relatively matured now [161]. Microalgae are currently used
both as dried whole algae and as the source for the extraction of high-valued food supplements, such
as carotenoids and omega-3 fatty acids. A majority of microalgae used belong to the genera Chlorella,
Dunaliella, Spirulina, Haematococcus, Isochrysis and Schizochytrium [162]. Chlorella and Spirulina are the
most-marketed algae worldwide. The production of Chlorella is centered in Asia, while Spirulina is
produced in Asia, as well as the USA; although both of these microalgae are also produced in a few
other countries with warm climates [163]. Both Chlorella and Spirulina rank first in the microalgal
biomass production rate worldwide (5000 and 2000 tons of dry weight/year, respectively), with
estimated production values of about $40 million/year for each [164]. In food, carotenoids serve as
the precursors to aroma compounds and also as natural antioxidants that may help prolong the shelf
life of food products [165]. Therefore, Portugal [9,166,167] proposed to utilize microalgal biomass as
pigments and functional ingredients in food products. The biomass of C. vulgaris and H. pluvialis has
been incorporated into pea protein-stabilized emulsions, achieving a considerable compromise between
the stability and the sensory properties. The C. vulgaris biomass, with organoleptic characteristics that
are acceptable to consumers, was used as a source of natural green pigment to color Christmas cookies.
A fishy taste and a powdery consistency are a few inconveniences caused by the incorporation of
microalgal biomass in traditional food products. It may be necessary to address the issues concerning
these organoleptic characteristics, for the food products to be accepted by many consumers [147]. In
the traditional cuisines of Asian countries, algae have been a common ingredient. As a result, the
addition of microalgae to food is not perceived as a strong change and is appreciated by the consumers
in these countries [168]. In Western nations, however, microalgae are considered a novel ingredient,
and their addition to food has not been accepted yet.
Instead of using the whole biomass, Gantar and Svircev [169] suggested employing the microalgal
biomass as a source of biomolecules of interest, so that it would be accepted by consumers [162].
Microalgae-based high-valued molecules have been produced on a smaller scale, with a larger market
potential, mainly in Asia, the USA and Australia. Although the production costs are high, the quality
of biomolecules produced is better than that from the alternative methods, such as chemical synthesis
or the extraction from plants; this is mainly because the molecules produced from the microalgal
biomass is more effective for food applications compared to their synthetic variants [170]. The most
important molecules from the microalgal biomass that are currently on the market are carotenoids and
fatty acids used as dietary supplements. Astaxanthin from dried H. pluvialis, which is used as a food
additive or as a dietary supplement, is the most-developed product from this source [171].
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As a result of the development of novel eating habits among consumers who are now demanding
more sophisticated products, a few innovative food products that are enriched with microalgae have
been developed and positioned in this emerging functional food market. One good example is Spirulina,
an ingredient in beverages and shakes [162], which is used in combination with other ingredients. It is
available in New Zealand as Charlie’s Honest Superfood Spirulina and Fruit Smoothie. Coca-Cola’s
brand Odwalla manufactures a fruit juice drink with Spirulina as an ingredient [162]. Another example
is PepsiCo, 100% Juice Smoothie with Spirulina [172]. Nestle Rowntree reintroduced the blue Smarties
into the market after having identified the blue-green cyanobacteria as a natural source of the blue
color [173].
Besides the health interests, it is important to assess the toxicity of the natural compounds isolated
from microalgae (pigments, lipids, etc.), as certain compounds may accumulate in the human body,
and this could affect the safe usage of microalgae in food products for human consumption [174]. It is
undeniable that the interest in using microalgae or the other marine microorganisms as natural sources
for functional food ingredients is growing, and certain reasons that support this fact are as follows: the
number of marine species available and the prospect of discovering novel ones is significant [175], and
the management of growth conditions is able to assist the marine microorganisms in accumulating
bioactive compounds, which is helpful in economically-competitive processes [8,44,160].
Regulation
The regulations for the production of marine microbial biomass (or their bioactive compounds) are
poorly established, increasing the chaos worldwide in this regard. Besides, the laws and regulations
associated with food or food ingredients vary with different countries [176]. There are two EU
regulations for the production and marketing of microalgae-based products for food and feed: the
Food Safety Regulation (EC 178/2002) and the Novel Food Regulation (EC 258/97) (MB). The latter is
particularly relevant, as it provides the authorization procedures for all novel food and feed products.
In Europe, the first step to commercialize carotenoids or the microorganisms as food or food ingredients
is to identify whether they have been consumed to a significant degree before 15 May 1997 (the date
on which the regulation (EC) No. 258/97 entered into force), in at least one of the member states. If
this is the case, the food or the food ingredient should be considered the same as a conventional food,
if it demonstrates the same characteristics and composition as those of the conventional food. This
simplifies the http://www.linguee.es/ingles-espanol/traduccion/commercialization+process.html
commercialization process, and the food product may be positioned in the market within the EU
after notification to the European Commission [177]. Prior to commercializing any type of novel food
product (including the ones from microalgae), scientific evidence must be provided in order to confirm
that the novel food products are equivalent to the traditional ones (EC Regulation, 1997) [178].
In another scenario, if the food or the food ingredient is identified as a novel food, the further
procedure becomes complex. In order to introduce a novel food or food ingredient into the EU market,
prior authorization is required, which includes the manufacturing processes, as well as a rigorous
assessment of the toxicological, nutritional, compositional and other relevant data by the competent
authorities of the respective EU member state. In the event of commercialization of the microorganism
as a functional food, it must be demonstrated to affect one or more target functions in the body
beneficially. The functional foods are not allowed to be in the form of pills or capsules; they must
remain in the form of food. Furthermore, they must be demonstrated to achieve their effects when
used in an amount that would normally be expected to be consumed in the diet (EAS 2008) [164].
Regulations in the USA assess the food product, while those in Europe are focused on the
technology used to obtain the final food product. The competition from outside Europe (China and
the USA) is growing fast, and this is the right time for Europe to explore the opportunities to increase
the possibility of successful large-scale applications of microalgae and other marine microorganisms
in food [149]. The insufficient domestic demand for marine microalgal food products in Europe and
the difficulties in achieving commercial authorization due to the strict Novel Food regulation remain
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a challenge. In this regard, experts consider cost reductions, technical breakthroughs and achieving
better cooperation between academia and industries as the most important challenges in the near
future [164].
7. Conclusions
In the last few decades, the research on carotenoids, and their implementation in markets, have
advanced considerably. However, further advancement of this development is required, especially
in the processes used to obtain carotenoids; for example, chemical synthesis must be replaced by
biological production. In this way, the reduction in the costs of the production of carotenoids and in
the generation of non-active waste would be achieved.
Marine microorganisms offer numerous advantages as natural sources of carotenoids: they usually
have low nutritional requirements during their growth and cultivation, which reduces the production
costs; the culture medium in which they grow contains moderate or high salt concentrations, which
prevents contamination with other microorganisms, reducing the costs and facilitating the downstream
processes; these microorganisms are also a source of rare carotenoids, the properties of which are yet
to be explored, for example bacterioruberin from Haloarchaea.
In a more applied sense, it should be noted that an extensive bibliography is available on the
biochemical characteristics of carotenoids and their potential beneficial effects on human health.
However, further studies on the direct and real-time effects of carotenoids on human populations are
required, in order to corroborate their antioxidant, antitumor, anti-aging and various other roles. On
the nutritional level, the use of the carotenoids obtained from marine biomass is well studied; also,
their use is common in the diets of people in several countries, especially in Asia. The industry must
continue to take steps in the direction of improving the organoleptic properties, which are altered by
the addition of marine biomass to the conventional foods; especially in Europe, where such functional
foods are relatively recent and not yet completely accepted.
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